{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:49:33Z","timestamp":1785199773387,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:00:00Z","timestamp":1547856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00280-019-03773-x","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T03:06:21Z","timestamp":1547867181000},"page":"681-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["In vitro and in vivo anticancer effects of two quinoline\u2013platinum(II) complexes on human osteosarcoma models"],"prefix":"10.1007","volume":"83","author":[{"given":"Maria Carolina","family":"Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Resasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Laura","family":"Di Virgilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cavaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-3997","authenticated-orcid":false,"given":"Ignacio Esteban","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,19]]},"reference":[{"key":"3773_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573\u2013584. \n                    https:\/\/doi.org\/10.1038\/nrc2167","journal-title":"Nat Rev Cancer"},{"key":"3773_CR2","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1517\/14656566.2013.827171","volume":"14","author":"N Yamamoto","year":"2013","unstructured":"Yamamoto N, Tsuchiya H (2013) Chemotherapy for osteosarcoma\u2014where does it come from? What is it? Where is it going? Expert Opin Pharmacother 14:2183\u20132193. \n                    https:\/\/doi.org\/10.1517\/14656566.2013.827171","journal-title":"Expert Opin Pharmacother"},{"key":"3773_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/jbmr.77","volume":"25","author":"R Gorlick","year":"2010","unstructured":"Gorlick R, Khanna C (2010) Osteosarcoma. J Bone Miner Res 25:683\u2013691. \n                    https:\/\/doi.org\/10.1002\/jbmr.77","journal-title":"J Bone Miner Res"},{"key":"3773_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00003086-199901000-00005","volume":"358","author":"H Tsuchiya","year":"1999","unstructured":"Tsuchiya H, Tomita K, Mori Y et al (1999) Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop Relat Res 358:27\u201335","journal-title":"Clin Orthop Relat Res"},{"key":"3773_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2006.03.032","volume":"247","author":"AM Bode","year":"2007","unstructured":"Bode AM, Dong Z (2007) The enigmatic effects of caffeine in cell cycle and cancer. Cancer Lett 247:26\u201339. \n                    https:\/\/doi.org\/10.1016\/j.canlet.2006.03.032","journal-title":"Cancer Lett"},{"key":"3773_CR6","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.1051965","author":"CM Hattinger","year":"2015","unstructured":"Hattinger CM, Fanelli M, Tavanti E et al (2015) Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs. \n                    https:\/\/doi.org\/10.1517\/14728214.2015.1051965","journal-title":"Expert Opin Emerg Drugs"},{"key":"3773_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12032-013-0624-6","volume":"30","author":"A Durnali","year":"2013","unstructured":"Durnali A, Alkis N, Cangur S et al (2013) Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol 30:624. \n                    https:\/\/doi.org\/10.1007\/s12032-013-0624-6","journal-title":"Med Oncol"},{"key":"3773_CR8","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.2174\/138161210791034003","volume":"16","author":"I Holen","year":"2010","unstructured":"Holen I, Coleman RE (2010) Bisphosphonates as treatment of bone metastases. Curr Pharm Des 16:1262\u20131271","journal-title":"Curr Pharm Des"},{"key":"3773_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","volume":"126","author":"M McClung","year":"2013","unstructured":"McClung M, Harris ST, Miller PD et al (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126:13\u201320. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2012.06.023","journal-title":"Am J Med"},{"key":"3773_CR10","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1039\/b922222g","volume":"46","author":"Z Xue","year":"2010","unstructured":"Xue Z, Lin M, Zhu J et al (2010) Platinum(II) compounds bearing bone-targeting group: synthesis, crystal structure and antitumor activity. Chem Commun 46:1212. \n                    https:\/\/doi.org\/10.1039\/b922222g","journal-title":"Chem Commun"},{"key":"3773_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2174\/1871520615666141216151547","volume":"15","author":"K Igarashi","year":"2015","unstructured":"Igarashi K, Yamamoto N, Hayashi K et al (2015) Effectiveness of two novel anionic and cationic platinum complexes in the treatment of osteosarcoma. Anticancer Agents Med Chem 15:390\u2013399","journal-title":"Anticancer Agents Med Chem"},{"key":"3773_CR12","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","volume":"116","author":"TC Johnstone","year":"2016","unstructured":"Johnstone TC, Suntharalingam K, Lippard SJ (2016) The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 116:3436\u20133486. \n                    https:\/\/doi.org\/10.1021\/acs.chemrev.5b00597","journal-title":"Chem Rev"},{"key":"3773_CR13","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2147\/DDDT.S49763","volume":"7","author":"V Prachayasittikul","year":"2013","unstructured":"Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V (2013) 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther 7:1157\u20131178. \n                    https:\/\/doi.org\/10.2147\/DDDT.S49763","journal-title":"Drug Des Devel Ther"},{"key":"3773_CR14","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ejmech.2014.07.044","volume":"97","author":"O Afzal","year":"2015","unstructured":"Afzal O, Kumar S, Haider MR et al (2015) A review on anticancer potential of bioactive heterocycle quinoline. Eur J Med Chem 97:871\u2013910. \n                    https:\/\/doi.org\/10.1016\/j.ejmech.2014.07.044","journal-title":"Eur J Med Chem"},{"key":"3773_CR15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ccr.2007.06.003","volume":"252","author":"M Albrecht","year":"2008","unstructured":"Albrecht M, Fiege M, Osetska O (2008) 8-Hydroxyquinolines in metallosupramolecular chemistry. Coord Chem Rev 252:812\u2013824. \n                    https:\/\/doi.org\/10.1016\/j.ccr.2007.06.003","journal-title":"Coord Chem Rev"},{"key":"3773_CR16","doi-asserted-by":"publisher","first-page":"13343","DOI":"10.1039\/c3dt51720a","volume":"42","author":"C Mart\u00edn Santos","year":"2013","unstructured":"Mart\u00edn Santos C, Cabrera S, R\u00edos-Luci C et al (2013) Novel clioquinol and its analogous platinum complexes: importance, role of the halogen substitution and the hydroxyl group of the ligand. Dalton Trans 42:13343\u201313348. \n                    https:\/\/doi.org\/10.1039\/c3dt51720a","journal-title":"Dalton Trans"},{"key":"3773_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00441-012-1441-5","volume":"352","author":"H Page","year":"2013","unstructured":"Page H, Flood P, Reynaud EG (2013) Three-dimensional tissue cultures: current trends and beyond. Cell Tissue Res 352:123\u2013131. \n                    https:\/\/doi.org\/10.1007\/s00441-012-1441-5","journal-title":"Cell Tissue Res"},{"key":"3773_CR18","doi-asserted-by":"publisher","first-page":"e44640","DOI":"10.1371\/journal.pone.0044640","volume":"7","author":"WY Ho","year":"2012","unstructured":"Ho WY, Yeap SK, Ho CL et al (2012) Development of multicellular tumor spheroid (MCTS) culture from breast cancer cell and a high throughput screening method using the MTT assay. PLoS One 7:e44640. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0044640","journal-title":"PLoS One"},{"key":"3773_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nprot.2008.226","volume":"4","author":"J Friedrich","year":"2009","unstructured":"Friedrich J, Seidel C, Ebner R, Kunz-Schughart L (2009) Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4:309\u2013324. \n                    https:\/\/doi.org\/10.1038\/nprot.2008.226","journal-title":"Nat Protoc"},{"key":"3773_CR20","doi-asserted-by":"publisher","first-page":"13400","DOI":"10.1021\/ja076281t","volume":"129","author":"RA Alderden","year":"2007","unstructured":"Alderden RA, Mellor HR, Modok S et al (2007) Elemental tomography of cancer-cell spheroids reveals incomplete uptake of both platinum(II) and platinum(IV) complexes. J Am Chem Soc 129:13400\u201313401. \n                    https:\/\/doi.org\/10.1021\/ja076281t","journal-title":"J Am Chem Soc"},{"key":"3773_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.bjc.6603854","volume":"97","author":"S Modok","year":"2007","unstructured":"Modok S, Scott R, Alderden RA et al (2007) Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model. Br J Cancer 97:194\u2013200. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6603854","journal-title":"Br J Cancer"},{"key":"3773_CR22","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1021\/ic50112a025","volume":"11","author":"JH Price","year":"1972","unstructured":"Price JH, Williamson AN, Schramm RF, Wayland BB (1972) Palladium(II) and platinum(II) alkyl sulfoxide complexes. Examples of sulfur-bonded, mixed sulfur- and oxygen-bonded, and totally oxygen-bonded complexes. Inorg Chem 11:1280\u20131284. \n                    https:\/\/doi.org\/10.1021\/ic50112a025","journal-title":"Inorg Chem"},{"key":"3773_CR23","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1210\/endo.130.4.1372238","volume":"130","author":"T Okajima","year":"1992","unstructured":"Okajima T, Nakamura K, Zhang H et al (1992) Sensitive colorimetric bioassays for insulin-like growth factor (IGF) stimulation of cell proliferation and glucose consumption: use in studies of IGF analogs. Endocrinology 130:2201\u20132212. \n                    https:\/\/doi.org\/10.1210\/endo.130.4.1372238","journal-title":"Endocrinology"},{"key":"3773_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55\u201363","journal-title":"J Immunol Methods"},{"key":"3773_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0014-4827(88)90265-0","volume":"175","author":"NP Singh","year":"1988","unstructured":"Singh NP, McCoy MT, Tice RR, Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184\u2013191","journal-title":"Exp Cell Res"},{"key":"3773_CR26","doi-asserted-by":"publisher","unstructured":"Butenko N, Isabel A, Nouri O et al (2009) DNA cleavage activity of V IV O (acac) 2 and derivatives. 103:622\u2013632. \n                    https:\/\/doi.org\/10.1016\/j.jinorgbio.2009.01.003","DOI":"10.1016\/j.jinorgbio.2009.01.003"},{"key":"3773_CR27","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.1021\/bi00444a019","volume":"28","author":"J Bernadou","year":"1989","unstructured":"Bernadou J, Pratviel G, Bennis F et al (1989) Potassium monopersulfate and a water-soluble manganese porphyrin complex, [Mn(TMPyP)](OAc)5, as an efficient reagent for the oxidative cleavage of DNA. Biochemistry 28:7268\u20137275","journal-title":"Biochemistry"},{"key":"3773_CR28","doi-asserted-by":"publisher","first-page":"11868","DOI":"10.1039\/c3dt50524c","volume":"42","author":"IE Leon","year":"2013","unstructured":"Leon IE, Di Virgilio a L, Porro V et al (2013) Antitumor properties of a vanadyl(IV) complex with the flavonoid chrysin [VO(chrysin)2EtOH]2 in a human osteosarcoma model: the role of oxidative stress and apoptosis. Dalton Trans 42:11868\u201311880. \n                    https:\/\/doi.org\/10.1039\/c3dt50524c","journal-title":"Dalton Trans"},{"key":"3773_CR29","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00775-016-1397-0","volume":"21","author":"IE Le\u00f3n","year":"2016","unstructured":"Le\u00f3n IE, Cadavid-Vargas JF, Resasco A et al (2016) In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice. JBIC J Biol Inorg Chem 21:1009\u20131020. \n                    https:\/\/doi.org\/10.1007\/s00775-016-1397-0","journal-title":"JBIC J Biol Inorg Chem"},{"key":"3773_CR30","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1158\/1078-0432.CCR-08-2392","volume":"15","author":"TA ElBayoumi","year":"2009","unstructured":"ElBayoumi TA, Torchilin VP (2009) Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 15:1973\u20131980. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2392","journal-title":"Clin Cancer Res"},{"key":"3773_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0010-8545(00)80523-8","volume":"44","author":"PS Pregosin","year":"1982","unstructured":"Pregosin PS (1982) Platinum-195 nuclear magnetic resonance. Coord Chem Rev 44:247\u2013291. \n                    https:\/\/doi.org\/10.1016\/S0010-8545(00)80523-8","journal-title":"Coord Chem Rev"},{"key":"3773_CR32","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1039\/c2mt20091k","volume":"4","author":"IE Le\u00f3n","year":"2012","unstructured":"Le\u00f3n IE, Di Virgilio AL, Barrio DA et al (2012) Hydroxylamido-amino acid complexes of oxovanadium(V). Toxicological study in cell culture and in a zebrafish model. Metallomics 4:1287\u20131296. \n                    https:\/\/doi.org\/10.1039\/c2mt20091k","journal-title":"Metallomics"},{"key":"3773_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10637-016-0337-8","volume":"34","author":"LS Flocke","year":"2016","unstructured":"Flocke LS, Trondl R, Jakupec MA, Keppler BK (2016) Molecular mode of action of NKP-1339\u2014a clinically investigated ruthenium-based drug\u2014involves ER- and ROS-related effects in colon carcinoma cell lines. Invest New Drugs 34:261\u2013268. \n                    https:\/\/doi.org\/10.1007\/s10637-016-0337-8","journal-title":"Invest New Drugs"},{"key":"3773_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jinorgbio.2016.06.021","volume":"165","author":"A Terenzi","year":"2016","unstructured":"Terenzi A, Pirker C, Keppler BK, Berger W (2016) Anticancer metal drugs and immunogenic cell death. J Inorg Biochem 165:71\u201379. \n                    https:\/\/doi.org\/10.1016\/j.jinorgbio.2016.06.021","journal-title":"J Inorg Biochem"},{"key":"3773_CR35","doi-asserted-by":"publisher","first-page":"617207","DOI":"10.1155\/2015\/617207","volume":"2015","author":"T Kamogashira","year":"2015","unstructured":"Kamogashira T, Fujimoto C, Yamasoba T (2015) Reactive oxygen species, apoptosis, and mitochondrial dysfunction in hearing loss. Biomed Res Int 2015:617207. \n                    https:\/\/doi.org\/10.1155\/2015\/617207","journal-title":"Biomed Res Int"},{"key":"3773_CR36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/02656736.2014.971446","volume":"30","author":"IB Slimen","year":"2014","unstructured":"Slimen IB, Najar T, Ghram A et al (2014) Reactive oxygen species, heat stress and oxidative-induced mitochondrial damage. A review. Int J Hyperthermia 30:513\u2013523. \n                    https:\/\/doi.org\/10.3109\/02656736.2014.971446","journal-title":"Int J Hyperthermia"},{"key":"3773_CR37","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1182\/blood.V98.9.2603","volume":"98","author":"I Herr","year":"2001","unstructured":"Herr I, Debatin KM (2001) Cellular stress response and apoptosis in cancer therapy. Blood 98:2603\u20132614","journal-title":"Blood"},{"key":"3773_CR38","first-page":"89","volume":"18","author":"B Mayer","year":"2003","unstructured":"Mayer B, Oberbauer R (2003) Mitochondrial regulation of apoptosis. News Physiol Sci 18:89\u201394","journal-title":"News Physiol Sci"},{"key":"3773_CR39","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1177\/1087057114532352","volume":"19","author":"A Walzl","year":"2014","unstructured":"Walzl A, Unger C, Kramer N et al (2014) The resazurin reduction assay can distinguish cytotoxic from cytostatic compounds in spheroid screening assays. J Biomol Screen 19:1047\u20131059. \n                    https:\/\/doi.org\/10.1177\/1087057114532352","journal-title":"J Biomol Screen"},{"key":"3773_CR40","doi-asserted-by":"publisher","first-page":"13463","DOI":"10.1021\/acs.est.5b03050","volume":"49","author":"JL Chen","year":"2015","unstructured":"Chen JL, Steele TWJ, Stuckey DC (2015) Modeling and application of a rapid fluorescence-based assay for biotoxicity in anaerobic digestion. Environ Sci Technol 49:13463\u201313471. \n                    https:\/\/doi.org\/10.1021\/acs.est.5b03050","journal-title":"Environ Sci Technol"},{"key":"3773_CR41","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s10637-015-0260-4","volume":"33","author":"E Schreiber-Brynzak","year":"2015","unstructured":"Schreiber-Brynzak E, Klapproth E, Unger C et al (2015) Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. Invest New Drugs 33:835\u2013847. \n                    https:\/\/doi.org\/10.1007\/s10637-015-0260-4","journal-title":"Invest New Drugs"},{"key":"3773_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2018.03.009","volume":"827","author":"F Shahid","year":"2018","unstructured":"Shahid F, Farooqui Z, Khan F (2018) Cisplatin-induced gastrointestinal toxicity: an update on possible mechanisms and on available gastroprotective strategies. Eur J Pharmacol 827:49\u201357. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2018.03.009","journal-title":"Eur J Pharmacol"},{"key":"3773_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1462802","volume":"2018","author":"M Per\u0161e","year":"2018","unstructured":"Per\u0161e M, Ve\u010deri\u0107-Haler \u017d (2018) Cisplatin-induced rodent model of kidney injury: characteristics and challenges. Biomed Res Int 2018:1\u201329. \n                    https:\/\/doi.org\/10.1155\/2018\/1462802","journal-title":"Biomed Res Int"},{"key":"3773_CR44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ejmech.2014.12.052","volume":"92","author":"Q-P Qin","year":"2015","unstructured":"Qin Q-P, Chen Z-F, Qin J-L et al (2015) Studies on antitumor mechanism of two planar platinum(II) complexes with 8-hydroxyquinoline: synthesis, characterization, cytotoxicity, cell cycle and apoptosis. Eur J Med Chem 92:302\u2013313. \n                    https:\/\/doi.org\/10.1016\/j.ejmech.2014.12.052","journal-title":"Eur J Med Chem"},{"key":"3773_CR45","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","volume":"77","author":"S Dilruba","year":"2016","unstructured":"Dilruba S, Kalayda GV (2016) Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol 77:1103\u20131124. \n                    https:\/\/doi.org\/10.1007\/s00280-016-2976-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"3773_CR46","doi-asserted-by":"publisher","first-page":"e1208876","DOI":"10.1080\/2162402X.2016.1208876","volume":"5","author":"NB Roberts","year":"2016","unstructured":"Roberts NB, Wadajkar AS, Winkles JA et al (2016) Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma. Oncoimmunology 5:e1208876. \n                    https:\/\/doi.org\/10.1080\/2162402X.2016.1208876","journal-title":"Oncoimmunology"},{"key":"3773_CR47","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1097\/CAD.0b013e3283650bda","volume":"24","author":"A Ruggiero","year":"2013","unstructured":"Ruggiero A, Trombatore G, Triarico S et al (2013) Platinum compounds in children with cancer. Anticancer Drugs 24:1007\u20131019. \n                    https:\/\/doi.org\/10.1097\/CAD.0b013e3283650bda","journal-title":"Anticancer Drugs"},{"key":"3773_CR48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3109\/10408441003601836","volume":"40","author":"A Brozovic","year":"2010","unstructured":"Brozovic A, Ambriovi\u0107-Ristov A, Osmak M (2010) The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol 40:347\u2013359. \n                    https:\/\/doi.org\/10.3109\/10408441003601836","journal-title":"Crit Rev Toxicol"},{"key":"3773_CR49","first-page":"1381","volume":"34","author":"H Fujii","year":"2009","unstructured":"Fujii H, Honoki K, Tsujiuchi T et al (2009) Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol 34:1381\u20131386","journal-title":"Int J Oncol"},{"key":"3773_CR50","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2174\/138945012803530152","volume":"13","author":"SP Langdon","year":"2012","unstructured":"Langdon SP (2012) Animal modeling of cancer pathology and studying tumor response to therapy. Curr Drug Targets 13:1535\u20131547","journal-title":"Curr Drug Targets"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03773-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T09:22:30Z","timestamp":1580721750000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03773-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,19]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["3773"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03773-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,19]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, USA 2002. Laboratory Animals. A.A Tuffery, 1995. London: John Wiley). All efforts were made to minimize animal suffering, to decrease the number of animals used, and to utilize possible alternatives to in vivo techniques.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}}]}}